Posted Mar 22, 2013 8:48 UTC (Fri) by lacos (subscriber, #70616)
[Link]
It wouldn't prevent them (or a 3rd party merchant) from reimporting and reselling more cheaply. Perhaps the subsidized pharmaceuticals should only be sold to patients ("end users") in the target country, but that's again a trade barrier, only not between countries.
Upholding the first sale doctrine
Posted Mar 22, 2013 18:55 UTC (Fri) by nix (subscriber, #2304)
[Link]
... or you decide to eat the loss because the alternative is the poor country compulsorily licensing your patent and farming it out to a much cheaper generic manufacturer. Of course, a lot of patent treaty sorts *hate* this, but it's still there, and India and others have used it. It's amazing how fast the licensing fees demanded dropped when they did so.